Design and synthesis of novel anti-urease imidazothiazole derivatives with promising antibacterial activity against Helicobacter pylori.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
04
2023
accepted:
21
05
2023
medline:
5
6
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
epublish
Résumé
Urease enzyme is a known therapeutic drug target for treatment of Helicobacter pylori infection due to its role in settlement and growth in gastric mucosa. In this study, we designed a new series of sulfonates and sulfamates bearing imidazo[2,1-b]thiazole scaffold that exhibit a potent inhibitory activity of urease enzyme. The most potent compound 2c inhibited urease with an IC50 value of 2.94 ± 0.05 μM, which is 8-fold more potent than the thiourea positive control (IC50 = 22.3 ± 0.031 μM). Enzyme kinetics study showed that compound 2c is a competitive inhibitor of urease. Molecular modeling studies of the most potent inhibitors in the urease active site suggested multiple binding interactions with different amino acid residues. Phenotypic screening of the developed compounds against H. pylori delivered molecules of that possess high potency (1a, 1d, 1h, 2d, and 2f) in comparison to the positive control, acetohydroxamic acid. Additional studies to investigate the selectivity of these compounds against AGS gastric cell line and E. coli were performed. Permeability of the most promising derivatives (1a, 1d, 1h, 2d, and 2f) in Caco-2 cell line, was investigated. As a result, compound 1d presented itself as a lead drug candidate since it exhibited a promising inhibition against urease with an IC50 of 3.09 ± 0.07 μM, MIC value against H. pylori of 0.031 ± 0.011 mM, and SI against AGS of 6.05. Interestingly, compound 1d did not show activity against urease-negative E. coli and exhibited a low permeability in Caco-2 cells which supports the potential use of this compound for GIT infection without systemic effect.
Identifiants
pubmed: 37267378
doi: 10.1371/journal.pone.0286684
pii: PONE-D-23-10424
pmc: PMC10237672
doi:
Substances chimiques
Urease
EC 3.5.1.5
Anti-Bacterial Agents
0
Enzyme Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0286684Informations de copyright
Copyright: © 2023 Shahin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Microbiol Rev. 1989 Mar;53(1):85-108
pubmed: 2651866
Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5
pubmed: 1673839
Bioorg Med Chem. 2015 Sep 1;23(17):6049-58
pubmed: 26081763
Arch Pharm (Weinheim). 2013 Jun;346(6):423-46
pubmed: 23712847
Int J Biol Macromol. 2016 Oct;91:680-95
pubmed: 27262516
Bioorg Med Chem. 2014 Jul 15;22(14):3703-12
pubmed: 24878361
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):383-384
pubmed: 28465548
Bioorg Med Chem. 2016 May 15;24(10):2318-29
pubmed: 27068142
Virol J. 2011 May 26;8:260
pubmed: 21612660
J Mol Biol. 2010 Jul 16;400(3):274-83
pubmed: 20471401
ChemMedChem. 2016 Jun 6;11(11):1117-21
pubmed: 27218427
J Mol Biol. 2010 Jul 16;400(3):502-17
pubmed: 20488190
Int J Cancer. 2015 Jan 15;136(2):487-90
pubmed: 24889903
RSC Adv. 2020 Dec 15;10(72):44247-44311
pubmed: 35557843
Nat Commun. 2021 Jan 11;12(1):230
pubmed: 33431861
Infect Immun. 1991 Jul;59(7):2470-5
pubmed: 2050411
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
J Biol Inorg Chem. 2001 Mar;6(3):300-14
pubmed: 11315566
J Med Chem. 2018 Dec 27;61(24):10996-11020
pubmed: 30024747
Molecules. 2019 Oct 25;24(21):
pubmed: 31731387
J Comput Aided Mol Des. 1990 Dec;4(4):355-67
pubmed: 2092081
Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
pubmed: 15272157
J Med Chem. 2014 Dec 26;57(24):10257-74
pubmed: 25255204
Eur J Pharmacol. 2005 Jan 31;508(1-3):31-45
pubmed: 15680252
Expert Opin Ther Pat. 2011 Jun;21(6):945-57
pubmed: 21457123
World J Gastroenterol. 2018 Aug 7;24(29):3204-3221
pubmed: 30090002
Toxicon. 2016 Feb;110:90-109
pubmed: 26690979
J Clin Gastroenterol. 1995;21 Suppl 1:S160-3
pubmed: 8775011
J Clin Pathol. 2010 May;63(5):424-30
pubmed: 20418234
J Biol Inorg Chem. 2013 Mar;18(3):391-9
pubmed: 23412551
Eur J Med Chem. 2021 Nov 15;224:113674
pubmed: 34237622
Pathogens. 2019 Apr 01;8(2):
pubmed: 30939800
J Chem Theory Comput. 2012 Jun 12;8(6):1853-64
pubmed: 26593820
Bioorg Chem. 2018 Sep;79:34-45
pubmed: 29723741
Eur J Med Chem. 2014 Mar 3;74:314-23
pubmed: 24486414
Med Chem Res. 2013 Aug;22(8):3629-3639
pubmed: 23807823
Bioorg Chem. 2018 Sep;79:363-371
pubmed: 29859384
Gastroenterology. 2017 Aug;153(2):420-429
pubmed: 28456631
Bioorg Med Chem Lett. 2009 Jul 1;19(13):3615-8
pubmed: 19447621
J Med Chem. 2021 Oct 14;64(19):14046-14128
pubmed: 34591488
Eur J Med Chem. 2009 Oct;44(10):4235-43
pubmed: 19552984
Int J Biol Macromol. 2022 Feb 15;198:157-167
pubmed: 34953808
J Biol Inorg Chem. 2015 Apr;20(3):541-54
pubmed: 25604966
Bioorg Med Chem. 2004 Mar 1;12(5):1257-64
pubmed: 14980637
Antibiotics (Basel). 2020 Jul 23;9(8):
pubmed: 32717826
Eur J Med Chem. 2019 Oct 15;180:486-508
pubmed: 31330449
Microbiol Rev. 1995 Sep;59(3):451-80
pubmed: 7565414
Eur J Med Chem. 2011 Dec;46(12):5769-77
pubmed: 22033063
J Biomol Struct Dyn. 2021 Nov;39(18):7107-7122
pubmed: 32799758
Bioorg Chem. 2022 Feb;119:105545
pubmed: 34915286